Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer
AssigneeAdalta Limited
InventorsMichael Foley, Andrew Pow, Katherine Griffiths, Samantha Cobb, Katerina Viduka
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.
Claims12
A polypeptide which binds to human C-X-C chemokine receptor type 4 (CXCR4) comprising:
- a scaffold region and first and second binding loop regions contained therein, wherein the scaffold region comprises a sequence which has at least 80% identity to the scaffold region defined by amino acids 1 to 26, 33 to 79 and 88 to 97 of SEQ ID NO:1, and wherein the first binding loop region comprises the sequence of SEQ ID NO:41 and the second binding loop region comprises the sequence of SEQ ID NO:42.
A polypeptide comprising a sequence having at least 95% identity to SEQ ID NO:40.
Dependencies are inferred from the claim text.